On July 28, 2023 EpiAxis Therapeutics reported its participation in the Venture & Capital Sydney investor conference, scheduled for Thursday, 3 August 2023 (Press release, EpiAxis Therapeutics, JUL 28, 2023, View Source;utm_medium=rss&utm_campaign=epiaxis-heads-to-venture-and-capital-sydney-investor-conference [SID1234633481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be held at Hilton Sydney, located at 488 George St, Sydney NSW, from 9am to 6pm. This conference provides a fantastic opportunity to connect with investors and our CEO Dr Jeremy Chrisp would be delighted to speak with attendees at the event.

Venture and Capital 2023 is an exclusive conference designed to empower high-net-worth VCs, Family Offices and professional investors lwith unparalleled access to investment opportunities and exclusive networking.

EpiAxis will be highlighting its disruptive epigenetic approach to overcome treatment resistance and prevent cancer recurrence at the conference.